Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Scand J Gastroenterol

Retrieve available abstracts of 180 articles:
HTML format



Single Articles


    May 2020
  1. KOTANI S, Fukuba N, Kawashima K, Mishima Y, et al
    Prevalence of functional dyspepsia-like symptoms in ulcerative colitis patients in clinical remission and overlap with irritable bowel syndrome-like symptoms.
    Scand J Gastroenterol. 2020 May 15:1-5. doi: 10.1080/00365521.2020.1761998.
    PubMed     Abstract available


    April 2020
  2. RONNBLOM A, Karlbom U
    Acute severe attacks of ulcerative colitis in a population-based cohort: epidemiology, treatment and outcome.
    Scand J Gastroenterol. 2020 Apr 27:1-5. doi: 10.1080/00365521.2020.1757143.
    PubMed     Abstract available


    March 2020
  3. SOLBERG F, Ohlsson B
    Microscopic colitis and its associations with complications observed in classic inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2020 Mar 17:1-9. doi: 10.1080/00365521.2020.1739325.
    PubMed     Abstract available


  4. SOBOLEWSKA-WLODARCZYK A, Wlodarczyk M, Zielinska A, Siwinski P, et al
    Circadian rhythm abnormalities in patients with inflammatory bowel disease - association with adipokine profile.
    Scand J Gastroenterol. 2020 Mar 17:1-7. doi: 10.1080/00365521.2020.1737727.
    PubMed     Abstract available


  5. ZOU Y, Wu L, Xu W, Zhou X, et al
    Correlation between antibiotic use in childhood and subsequent inflammatory bowel disease: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2020 Mar 17:1-11. doi: 10.1080/00365521.2020.1737882.
    PubMed     Abstract available


  6. COENEN S, Nijns E, Weyts E, Geens P, et al
    Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy.
    Scand J Gastroenterol. 2020 Mar 17:1-7. doi: 10.1080/00365521.2020.1735506.
    PubMed     Abstract available


  7. MAK JWY, So J, Tang W, Yip TCF, et al
    Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
    Scand J Gastroenterol. 2020 Mar 2:1-8. doi: 10.1080/00365521.2020.1731760.
    PubMed     Abstract available


  8. ALULIS S, Vadstrup K, Borsi A, Nielsen A, et al
    Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Scand J Gastroenterol. 2020 Mar 2:1-7. doi: 10.1080/00365521.2020.1726445.
    PubMed     Abstract available


    February 2020
  9. GARSHOL BF, Aamodt G, Madsen C, Vatn MH, et al
    The effect of nitrogen dioxide on low birth weight in women with inflammatory bowel disease: a Norwegian pregnancy cohort study (MoBa).
    Scand J Gastroenterol. 2020 Feb 17:1-7. doi: 10.1080/00365521.2020.1726446.
    PubMed     Abstract available


  10. HOSSAIN A, Lordal M, Olsson AE, Storlahls A, et al
    Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease().
    Scand J Gastroenterol. 2020 Feb 13:1-6. doi: 10.1080/00365521.2020.1722738.
    PubMed     Abstract available


  11. SIGURDSSON GV, Schmidt S, Mellstrom D, Ohlsson C, et al
    Altered body composition profiles in young adults with childhood-onset inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Feb 1:1-9. doi: 10.1080/00365521.2020.1716061.
    PubMed     Abstract available


    January 2020
  12. KIM ES, Lee HS, Kim SK, Kim EY, et al
    Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study.
    Scand J Gastroenterol. 2020 Jan 26:1-6. doi: 10.1080/00365521.2020.1714716.
    PubMed     Abstract available


  13. ANGELISON L, Almer S, Davidsdottir L, Hammarlund P, et al
    Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study.
    Scand J Gastroenterol. 2020 Jan 21:1-9. doi: 10.1080/00365521.2020.1713210.
    PubMed     Abstract available


  14. VADSTRUP K, Alulis S, Borsi A, Elkjaer Stallknecht S, et al
    Societal costs attributable to Crohn's disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002-2016.
    Scand J Gastroenterol. 2020 Jan 21:1-6. doi: 10.1080/00365521.2019.1707276.
    PubMed     Abstract available


  15. AMOUZADEH-GHADIKOLAI O, Reicht G, Quehenberger F, Robier C, et al
    Basophilia of the peripheral blood in patients with ulcerative colitis.
    Scand J Gastroenterol. 2020 Jan 12:1-3. doi: 10.1080/00365521.2019.1710247.
    PubMed     Abstract available


  16. ARKTEG CB, Goll R, Gundersen MD, Anderssen E, et al
    Mucosal gene transcription of ulcerative colitis in endoscopic remission.
    Scand J Gastroenterol. 2020 Jan 9:1-9. doi: 10.1080/00365521.2019.1710245.
    PubMed     Abstract available


    December 2019
  17. PIGNICZKI D, Rutka M, Farkas K, Molnar T, et al
    Lupus-like reactions in patients with inflammatory bowel disease: a little bit different data from another center.
    Scand J Gastroenterol. 2019 Dec 9:1. doi: 10.1080/00365521.2019.1690038.
    PubMed    


  18. RYHLANDER J, Ringstrom G, Simren M, Stotzer PO, et al
    Undergoing repeated colonoscopies - experiences from patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Dec 9:1-6. doi: 10.1080/00365521.2019.1698649.
    PubMed     Abstract available


    November 2019
  19. YILMAZ KARADAG F, Arslan F, Caskurlu H, Cag Y, et al
    Efficacy of antiviral treatment in cytomegalovirus detected ulcerative colitis: meta-analysis of available data.
    Scand J Gastroenterol. 2019 Nov 13:1-7. doi: 10.1080/00365521.2019.1688860.
    PubMed     Abstract available


    October 2019
  20. SEGERMAN F, Clarkson S, Sjoberg K
    Marked regional variations in the prevalence of inflammatory bowel disease in a limited geographical region are not associated with compounds in the drinking water.
    Scand J Gastroenterol. 2019 Oct 15:1-11. doi: 10.1080/00365521.2019.1674374.
    PubMed     Abstract available


  21. AMCOFF K, Cao Y, Zhulina Y, Lampinen M, et al
    Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Oct 2:1-8. doi: 10.1080/00365521.2019.1670251.
    PubMed     Abstract available


    September 2019
  22. BODINI G, Demarzo MG, Saracco M, Coppo C, et al
    High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Sep 25:1-6. doi: 10.1080/00365521.2019.1666914.
    PubMed     Abstract available


  23. RIBALDONE DG, Vernero M, Parisi S, Ditto MC, et al
    Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients.
    Scand J Gastroenterol. 2019 Sep 24:1-4. doi: 10.1080/00365521.2019.1668052.
    PubMed     Abstract available


  24. MALHAM M, Carlsen K, Riis L, Paerregaard A, et al
    Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis.
    Scand J Gastroenterol. 2019 Sep 17:1-6. doi: 10.1080/00365521.2019.1665097.
    PubMed     Abstract available


  25. LUDVIGSSON JF, Andersson M, Bengtsson J, Eberhardson M, et al
    Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register.
    Scand J Gastroenterol. 2019 Sep 9:1-13. doi: 10.1080/00365521.2019.1660799.
    PubMed     Abstract available


  26. MACALUSO FS, Sapienza C, Ventimiglia M, Renna S, et al
    Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort.
    Scand J Gastroenterol. 2019 Sep 6:1-5. doi: 10.1080/00365521.2019.1663260.
    PubMed     Abstract available


    August 2019
  27. TENCA A, Jaakkola T, Farkkila M, Arola J, et al
    Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland.
    Scand J Gastroenterol. 2019 Aug 10:1-7. doi: 10.1080/00365521.2019.1648547.
    PubMed     Abstract available


    July 2019
  28. OH SJ, Lee CK, Kim YW, Jeong SJ, et al
    True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center.
    Scand J Gastroenterol. 2019 Jul 29:1-8. doi: 10.1080/00365521.2019.1646798.
    PubMed     Abstract available


  29. MALHAM M, Lilje B, Houen G, Winther K, et al
    The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Jul 22:1-7. doi: 10.1080/00365521.2019.1644368.
    PubMed     Abstract available


  30. CARMONA-ABELLAN M, Rodriguez-Lago I, Cabriada JL, Gomez-Esteban JC, et al
    The relationship between inflammatory bowel disease and Parkinson's disease: true or fiction?
    Scand J Gastroenterol. 2019 Jul 17:1-4. doi: 10.1080/00365521.2019.1641739.
    PubMed     Abstract available


  31. MENDALL M, Jensen CB, Angquist LH, Baker JL, et al
    Childhood growth and risk of inflammatory bowel disease: a population-based study of 317,030 children.
    Scand J Gastroenterol. 2019 Jul 11:1-6. doi: 10.1080/00365521.2019.1635201.
    PubMed     Abstract available


  32. MOLANDER P, Ylanne K
    Impact of ulcerative colitis on patients' lives: results of the Finnish extension of a global ulcerative colitis narrative survey.
    Scand J Gastroenterol. 2019 Jul 7:1-7. doi: 10.1080/00365521.2019.1635637.
    PubMed     Abstract available


  33. PUOLANNE AM, Kolho KL, Alfthan H, Farkkila M, et al
    Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study.
    Scand J Gastroenterol. 2019 Jul 2:1-6. doi: 10.1080/00365521.2019.1618910.
    PubMed     Abstract available


    June 2019
  34. YLISAUKKO-OJA T, Torvinen S, Ventola H, Schmidt S, et al
    Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab().
    Scand J Gastroenterol. 2019 Jun 16:1-7. doi: 10.1080/00365521.2019.1627579.
    PubMed     Abstract available


  35. VAN ASSELDONK DP, Simsek M, de Boer NKH, Jharap B, et al
    Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2019 Jun 16:1-8. doi: 10.1080/00365521.2019.1629006.
    PubMed     Abstract available


    May 2019
  36. NARULA N, Lauzon B, Marshall JK
    Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 30:1-6. doi: 10.1080/00365521.2019.1621367.
    PubMed     Abstract available


  37. KOLEHMAINEN S, Lepisto A, Farkkila M
    Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016().
    Scand J Gastroenterol. 2019 May 28:1-5. doi: 10.1080/00365521.2019.1620326.
    PubMed     Abstract available


  38. BERENDS SE, Strik AS, Jansen JM, de Boer NK, et al
    Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
    Scand J Gastroenterol. 2019 May 27:1-7. doi: 10.1080/00365521.2019.1619828.
    PubMed     Abstract available


  39. COENEN S, Weyts E, Geens P, Vermeire S, et al
    Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 18:1-5. doi: 10.1080/00365521.2019.1616214.
    PubMed     Abstract available


  40. LIU Y, Liu X
    Research progress of P2X7 receptor in inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 6:1-7. doi: 10.1080/00365521.2019.1609077.
    PubMed     Abstract available


  41. CHEN HX, Yuan ZY, Wu KX, Liu C, et al
    The study of methylation and single nucleotide polymorphisms of cancer-related genes in patients with early-stage ulcerative colitis.
    Scand J Gastroenterol. 2019 May 2:1-5. doi: 10.1080/00365521.2019.1594355.
    PubMed     Abstract available


    April 2019
  42. DILILLO D, Zuccotti GV, Galli E, Meneghin F, et al
    Noninvasive testing in the management of children with suspected inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Apr 28:1-6. doi: 10.1080/00365521.2019.1604799.
    PubMed     Abstract available


  43. SARAIVA S, Cortez-Pinto J, Barosa R, Castela J, et al
    Evaluation of fatigue in inflammatory bowel disease - a useful tool in daily practice.
    Scand J Gastroenterol. 2019 Apr 23:1-6. doi: 10.1080/00365521.2019.1602669.
    PubMed     Abstract available


  44. RODRIGUEZ-LAGO I, Sempere L, Gutierrez A, Nunez A, et al
    Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis.
    Scand J Gastroenterol. 2019 Apr 14:1-6. doi: 10.1080/00365521.2019.1600715.
    PubMed     Abstract available


  45. COLD F, Browne PD, Gunther S, Halkjaer SI, et al
    Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated - an open-label pilot study.
    Scand J Gastroenterol. 2019 Apr 4:1-8. doi: 10.1080/00365521.2019.1585939.
    PubMed     Abstract available


  46. RIBALDONE DG, Pellicano R, Vernero M, Caviglia GP, et al
    Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Scand J Gastroenterol. 2019 Apr 4:1-7. doi: 10.1080/00365521.2019.1597159.
    PubMed     Abstract available


    March 2019
  47. NIELSEN HM, Dalager-Pedersen M, Nielsen H
    Risk of inflammatory bowel disease after Campylobacter jejuni and Campylobacter concisus infection: a population-based cohort study.
    Scand J Gastroenterol. 2019 Mar 24:1-8. doi: 10.1080/00365521.2019.1578406.
    PubMed     Abstract available


  48. SAFAEIAN R, Howarth GS, Lawrance IC, Trinder D, et al
    Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis.
    Scand J Gastroenterol. 2019 Mar 23:1-8. doi: 10.1080/00365521.2019.1581253.
    PubMed     Abstract available


  49. BOTS SJ, Kuin S, Ponsioen CY, Gecse KB, et al
    Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
    Scand J Gastroenterol. 2019;54:281-288.
    PubMed     Abstract available


    February 2019
  50. VENTURIERI MO, Komati JTS, Lopes LHC, Sdepanian VL, et al
    Treatment with Noripurum EV((R)) is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia.
    Scand J Gastroenterol. 2019 Feb 20:1-7. doi: 10.1080/00365521.2019.1570326.
    PubMed     Abstract available


  51. DIGNASS AU, Siegmund B, Goertz R, Schneidewind G, et al
    Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Scand J Gastroenterol. 2019 Feb 8:1-10. doi: 10.1080/00365521.2019.1569124.
    PubMed     Abstract available


  52. KJAER MD, Qvist N, Nordgaard-Lassen I, Christensen LA, et al
    Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial.
    Scand J Gastroenterol. 2019;54:188-193.
    PubMed     Abstract available


    January 2019
  53. EVERHOV AH, Sachs MC, Malmborg P, Nordenvall C, et al
    Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients.
    Scand J Gastroenterol. 2019 Jan 31:1-9. doi: 10.1080/00365521.2018.1564361.
    PubMed     Abstract available


  54. MOHAN LJ, Daly JS, Ryan BM, Ramtoola Z, et al
    The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Jan 24:1-9. doi: 10.1080/00365521.2018.1563805.
    PubMed     Abstract available


  55. BUER LCT, Moum BA, Cvancarova M, Warren DJ, et al
    Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
    Scand J Gastroenterol. 2019 Jan 16:1-8. doi: 10.1080/00365521.2018.1548646.
    PubMed     Abstract available


  56. VESTERGAARD T, Jorgensen SMD, Christensen LA, Julsgaard M, et al
    Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX.
    Scand J Gastroenterol. 2019 Jan 6:1-4. doi: 10.1080/00365521.2018.1533583.
    PubMed     Abstract available


  57. MOLANDER P, Jussila A, Toivonen T, Makkeli P, et al
    The impacts of an inflammatory bowel disease nurse specialist on the quality of care and costs in Finland.
    Scand J Gastroenterol. 2019 Jan 2:1-6. doi: 10.1080/00365521.2018.1541477.
    PubMed     Abstract available


  58. CHOUKOUR M, Kivits J, Baker A, Baumann C, et al
    Personalised medicine in inflammatory bowel diseases: a patient survey.
    Scand J Gastroenterol. 2019;54:135.
    PubMed    


  59. MONTEIRO S, Dias de Castro F, Leite S, Moreira MJ, et al
    Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
    Scand J Gastroenterol. 2019;54:49-54.
    PubMed     Abstract available


    December 2018
  60. PROUDFOOT H, Norton C, Artom M, Didymus E, et al
    Targets for interventions for faecal incontinence in inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2018;53:1476-1483.
    PubMed     Abstract available


    November 2018
  61. KALLA R, Boyapati R, Vatn S, Hijos G, et al
    Patients' perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey.
    Scand J Gastroenterol. 2018 Nov 18:1-6. doi: 10.1080/00365521.2018.1527394.
    PubMed     Abstract available


    October 2018
  62. TRONSTAD RR, Polushina T, Brattbakk HR, Stansberg C, et al
    Genetic and transcriptional analysis of inflammatory bowel disease-associated pathways in patients with GUCY2C-linked familial diarrhea.
    Scand J Gastroenterol. 2018 Oct 24:1-10. doi: 10.1080/00365521.2018.1521867.
    PubMed     Abstract available


  63. NISHIO M, Ishii Y, Hashimoto Y, Otake H, et al
    Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
    Scand J Gastroenterol. 2018 Oct 24:1-9. doi: 10.1080/00365521.2018.1511825.
    PubMed     Abstract available


  64. OSSUM AM, Palm O, Cvancarova M, Solberg IC, et al
    Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study.
    Scand J Gastroenterol. 2018 Oct 24:1-7. doi: 10.1080/00365521.2018.1518482.
    PubMed     Abstract available


  65. RUNDQUIST S, Eriksson C, Nilsson L, Angelison L, et al
    Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Scand J Gastroenterol. 2018 Oct 24:1-7. doi: 10.1080/00365521.2018.1519597.
    PubMed     Abstract available


  66. LEE JM, Kim YJ, Lee KM, Yoon H, et al
    Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 23:0-6. doi: 10.1080/00365521.2018.1524024.
    PubMed     Abstract available


  67. BAGER P, Vestergaard C, Juul T, Dahlerup JF, et al
    Population-based normative data for the inflammatory bowel disease fatigue scale - IBD-F.
    Scand J Gastroenterol. 2018 Oct 23:1-6. doi: 10.1080/00365521.2018.1521868.
    PubMed     Abstract available


  68. O'MORAIN N, O'Gorman S, McNamara D, Ryan B, et al
    Patients' attitudes toward treatment withdrawal in inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 9:1. doi: 10.1080/00365521.2018.1511827.
    PubMed    


  69. KATARINA PL, Sussanne B, Gunilla HF, Henrik H, et al
    The quality of care questionnaire: development of a valid measure for persons with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 9:1-8. doi: 10.1080/00365521.2018.1495759.
    PubMed     Abstract available


    September 2018
  70. STEIN J, Walper A, Klemm W, Farrag K, et al
    Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Scand J Gastroenterol. 2018 Sep 17:1-7. doi: 10.1080/00365521.2018.1498914.
    PubMed     Abstract available


  71. LIRHUS SS, Hoivik ML, Moum B, Melberg HO, et al
    Regional differences in anti-TNF-alpha therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study.
    Scand J Gastroenterol. 2018 Sep 12:1-6. doi: 10.1080/00365521.2018.1495258.
    PubMed     Abstract available


  72. HUGUET JM, Iborra M, Bosca-Watts MM, Maroto N, et al
    Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior?
    Scand J Gastroenterol. 2018 Sep 6:1-6. doi: 10.1080/00365521.2018.1501603.
    PubMed     Abstract available


  73. HAAPAMAKI J, Heikkinen E, Sipponen T, Roine RP, et al
    The impact of an adaptation course on health-related quality of life and functional capacity of patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Sep 2:1-5. doi: 10.1080/00365521.2018.1500639.
    PubMed     Abstract available


  74. JUDIT BERES N, Kiss Z, Muller KE, Cseh A, et al
    Role of microRNA-223 in the regulation of poly(ADP-ribose) polymerase in pediatric patients with Crohn's disease.
    Scand J Gastroenterol. 2018;53:1066-1073.
    PubMed     Abstract available


  75. SEGAL JP, Penez L, Mohsen Elkady S, Worley GHT, et al
    Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study.
    Scand J Gastroenterol. 2018;53:1051-1058.
    PubMed     Abstract available


  76. VERSTOCKT B, Vermeire S, Van Assche G, Ferrante M, et al
    When IBD is not IBD.
    Scand J Gastroenterol. 2018;53:1085-1088.
    PubMed     Abstract available


  77. LI H, Gong Y, Xie Y, Sun Q, et al
    Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis.
    Scand J Gastroenterol. 2018;53:1031-1042.
    PubMed     Abstract available


    August 2018
  78. BUHL S, Kristina Borghede M, Brynskov J, Steenholdt C, et al
    Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study.
    Scand J Gastroenterol. 2018;53:930-937.
    PubMed     Abstract available


  79. HOLLERAN G, Valerii G, Tortora A, Scaldaferri F, et al
    The use of single balloon enteroscopy in Crohn's disease and its impact on clinical outcome.
    Scand J Gastroenterol. 2018;53:925-929.
    PubMed     Abstract available


    July 2018
  80. VITIKAINEN K, Haapamaki J, Farkkila M, Anttila VJ, et al
    Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
    Scand J Gastroenterol. 2018 Jul 25:1-5. doi: 10.1080/00365521.2018.1492012.
    PubMed     Abstract available


  81. DROBNE D, Kurent T, Golob S, Svegl P, et al
    Success and safety of high infliximab trough levels in inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Jul 10:1-7. doi: 10.1080/00365521.2018.1486882.
    PubMed     Abstract available


  82. RIBALDONE DG, Vernero M, Astegiano M, Pellicano R, et al
    How ameliorate the adherence in patients with inflammatory bowel disease?
    Scand J Gastroenterol. 2018 Jul 3:1-2. doi: 10.1080/00365521.2018.1485731.
    PubMed    


  83. CARLSEN K, Riis LB, Elsberg H, Maagaard L, et al
    The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Scand J Gastroenterol. 2018 Jul 3:1-6. doi: 10.1080/00365521.2018.1482956.
    PubMed     Abstract available


    June 2018
  84. XIE D, Zhang Y, Qu H
    Crucial genes of inflammatory bowel diseases explored by gene expression profiling analysis.
    Scand J Gastroenterol. 2018;53:685-691.
    PubMed     Abstract available


  85. HOIVIK ML, Buer LCT, Cvancarova M, Warren DJ, et al
    Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Scand J Gastroenterol. 2018;53:692-699.
    PubMed     Abstract available


  86. YAKYMENKO O, Schoultz I, Gullberg E, Strom M, et al
    Infliximab restores colonic barrier to adherent-invasive E. coli in Crohn's disease via effects on epithelial lipid rafts.
    Scand J Gastroenterol. 2018;53:677-684.
    PubMed     Abstract available


  87. SEGAL JP, Chan H, Collins B, Faiz OD, et al
    Biofeedback in patients with ileoanal pouch dysfunction: a specialist centre experience.
    Scand J Gastroenterol. 2018;53:665-669.
    PubMed     Abstract available


  88. SCHULZE H, Esters P, Hartmann F, Stein J, et al
    A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients.
    Scand J Gastroenterol. 2018;53:670-676.
    PubMed     Abstract available


    May 2018
  89. YADAV A, Foromera J, Falchuk KR, Feuerstein JD, et al
    Biologics and immunomodulators for treating Crohn's disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature.
    Scand J Gastroenterol. 2018 May 2:1-5. doi: 10.1080/00365521.2018.1468478.
    PubMed     Abstract available


    April 2018
  90. YERUSHALMY-FELER A, Ben-Tov A, Weintraub Y, Amir A, et al
    High and low body mass index may predict severe disease course in children with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Apr 24:1-6. doi: 10.1080/00365521.2018.1464595.
    PubMed     Abstract available


  91. RATNAKUMARAN R, To N, Gracie DJ, Selinger CP, et al
    Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Scand J Gastroenterol. 2018 Apr 24:1-8. doi: 10.1080/00365521.2018.1464203.
    PubMed     Abstract available


  92. KANG EA, Yoon H, Seo AY, Shin CM, et al
    Characteristics of cytomegalovirus enterocolitis in patients with or without inflammatory bowel diseases.
    Scand J Gastroenterol. 2018;53:453-458.
    PubMed     Abstract available


  93. SONG EM, Kim N, Lee SH, Chang K, et al
    Clinical characteristics and long-term prognosis of elderly-onset Crohn's disease.
    Scand J Gastroenterol. 2018;53:417-425.
    PubMed     Abstract available


  94. XAVIER S, Curdia Goncalves T, Dias de Castro F, Magalhaes J, et al
    Perianal Crohn's disease - association with significant inflammatory activity in proximal small bowel segments.
    Scand J Gastroenterol. 2018;53:426-429.
    PubMed     Abstract available


    March 2018
  95. KEIL R, Wasserbauer M, Zadorova Z, Kojecky V, et al
    Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
    Scand J Gastroenterol. 2018 Mar 21:1-7. doi: 10.1080/00365521.2018.1451915.
    PubMed     Abstract available


  96. WICKBOM A, Bohr J, Nyhlin N, Eriksson A, et al
    Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature.
    Scand J Gastroenterol. 2018 Mar 16:1-7. doi: 10.1080/00365521.2018.1430252.
    PubMed     Abstract available


  97. AHLUWALIA B, Moraes L, Magnusson MK, Ohman L, et al
    Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
    Scand J Gastroenterol. 2018 Mar 9:1-11. doi: 10.1080/00365521.2018.1447597.
    PubMed     Abstract available


  98. DIGNASS A, Akbar A, Baumgart DC, Bommelaer G, et al
    Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis.
    Scand J Gastroenterol. 2018 Mar 7:1-7. doi: 10.1080/00365521.2018.1447598.
    PubMed     Abstract available


  99. ZAGOROWICZ E, Przybysz A, Szlak J, Magdziak A, et al
    Detection of cytomegalovirus by immunohistochemistry of colonic biopsies and quantitative blood polymerase chain reaction: evaluation of agreement in ulcerative colitis.
    Scand J Gastroenterol. 2018 Mar 7:1-7. doi: 10.1080/00365521.2018.1447596.
    PubMed     Abstract available


  100. AALTONEN G, Ristimaki A, Keranen I, Carpelan-Holmstrom M, et al
    Does a histologically inflamed resection margin increase postoperative complications in patients with Crohn's disease?
    Scand J Gastroenterol. 2018;53:279-283.
    PubMed     Abstract available


    February 2018
  101. KANGASPUNTA M, Haapamaki J, Farkkila M, Arkkila P, et al
    Inflammatory bowel disease and anemia: intravenous iron treatment.
    Scand J Gastroenterol. 2018 Feb 22:1-5. doi: 10.1080/00365521.2018.1441435.
    PubMed     Abstract available


  102. GREENSTEIN RJ, Brown ST
    A data-based hypothesis explicating the observations that "Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study".
    Scand J Gastroenterol. 2018 Feb 15:1. doi: 10.1080/00365521.2018.1440003.
    PubMed    


  103. HAKIMIAN S, Kheder J, Arum S, Cave DR, et al
    Re-evaluating osteoporosis and fracture risk in Crohn's disease patients in the era of TNF-alpha inhibitors.
    Scand J Gastroenterol. 2018;53:168-172.
    PubMed     Abstract available


    January 2018
  104. MOORE C
    Response to "Clinical implications of assay-specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time".
    Scand J Gastroenterol. 2018 Jan 31:1. doi: 10.1080/00365521.2018.1428400.
    PubMed    


  105. KLEPP P, Kisiel JB, Smastuen MC, Roseth A, et al
    Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
    Scand J Gastroenterol. 2018 Jan 9:1-6. doi: 10.1080/00365521.2018.1424935.
    PubMed     Abstract available


  106. LINDSTROM L, Jorgensen KK, Boberg KM, Castedal M, et al
    Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study.
    Scand J Gastroenterol. 2018 Jan 4:1-8. doi: 10.1080/00365521.2017.1421705.
    PubMed     Abstract available


  107. SUNDE ML, Ricanek P, Oresland T, Jahnsen J, et al
    Determinants of optimal bowel function in ileal pouch-anal anastomosis - physiological differences contributing to pouch function.
    Scand J Gastroenterol. 2018;53:8-14.
    PubMed     Abstract available


  108. PALATKA K, Kacska S, Lovas S, Garai I, et al
    The potential role of FDG PET-CT in the characterization of the activity of Crohn's disease, staging follow-up and prognosis estimation: a pilot study.
    Scand J Gastroenterol. 2018;53:24-30.
    PubMed     Abstract available


    December 2017
  109. SALIH A, Widbom L, Hultdin J, Karling P, et al
    Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study.
    Scand J Gastroenterol. 2017 Dec 21:1-6. doi: 10.1080/00365521.2017.1418904.
    PubMed     Abstract available


  110. YLISAUKKO-OJA T, Aaltonen J, Nuutinen H, Blomster T, et al
    High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)().
    Scand J Gastroenterol. 2017 Dec 19:1-10. doi: 10.1080/00365521.2017.1416160.
    PubMed     Abstract available


  111. RIBALDONE DG, Vernero M, Saracco GM, Pellicano R, et al
    The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets.
    Scand J Gastroenterol. 2017 Dec 11:1-6. doi: 10.1080/00365521.2017.1405070.
    PubMed     Abstract available


  112. LIMKETKAI BN, Sepulveda R, Hing T, Shah ND, et al
    Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Dec 7:1-5. doi: 10.1080/00365521.2017.1409364.
    PubMed     Abstract available


    November 2017
  113. GARCIA-PLANELLA E, Manosa M, Chaparro M, Beltran B, et al
    Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Scand J Gastroenterol. 2017 Nov 30:1-6. doi: 10.1080/00365521.2017.1410219.
    PubMed     Abstract available


  114. NISHIDA Y, Hosomi S, Watanabe K, Watanabe K, et al
    Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.
    Scand J Gastroenterol. 2017 Nov 24:1-7. doi: 10.1080/00365521.2017.1403647.
    PubMed     Abstract available


  115. KOMPEROD MJ, Sommer C, Mellin-Olsen T, Iversen PO, et al
    Persistent symptoms in patients with Crohn's disease in remission: An exploratory study on the role of diet.
    Scand J Gastroenterol. 2017 Nov 23:1-6. doi: 10.1080/00365521.2017.1397736.
    PubMed     Abstract available


  116. BAGER P, Chauhan U, Greveson K, Jaghult S, et al
    Systematic review: advice lines for patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Nov 13:1-7. doi: 10.1080/00365521.2017.1401116.
    PubMed     Abstract available


    October 2017
  117. THEOCHARI NA, Stefanopoulos A, Mylonas KS, Economopoulos KP, et al
    Antibiotics exposure and risk of inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2017 Oct 12:1-7. doi: 10.1080/00365521.2017.1386711.
    PubMed     Abstract available



  118. Correction to: Carvalho et al., Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease.
    Scand J Gastroenterol. 2017;52:ii.
    PubMed    


    September 2017
  119. KRIDIN K, Zelber-Sagi S, Comaneshter D, Cohen AD, et al
    Ulcerative colitis associated with pemphigus: a population-based large-scale study.
    Scand J Gastroenterol. 2017 Sep 28:1-5. doi: 10.1080/00365521.2017.1380839.
    PubMed     Abstract available


    August 2017
  120. EBERL A, Huoponen S, Pahikkala T, Blom M, et al
    Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2017 Aug 24:1-6. doi: 10.1080/00365521.2017.1369561.
    PubMed     Abstract available


  121. SAFFOURI G, Gupta A, Loftus EV Jr, Baddour LM, et al
    The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Aug 6:1-8. doi: 10.1080/00365521.2017.1362466.
    PubMed     Abstract available


    July 2017
  122. KHAJAH MA
    The potential role of fecal microbiota transplantation in the treatment of inflammatory Bowel disease.
    Scand J Gastroenterol. 2017 Jul 7:1-13. doi: 10.1080/00365521.2017.1347812.
    PubMed     Abstract available


    June 2017
  123. SMIDS C, Horjus Talabur Horje CS, Groenen MJM, van Koolwijk EHM, et al
    The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient.
    Scand J Gastroenterol. 2017 Jun 29:1-9. doi: 10.1080/00365521.2017.1344875.
    PubMed     Abstract available


  124. CARVALHO FSG, de Medeiros IA, Antunes H
    Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jun 23:1-5. doi: 10.1080/00365521.2017.1342137.
    PubMed     Abstract available



  125. Correction to: Kokkinidis DG, et al. Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 Jun 23:1. doi: 10.1080/00365521.2017.1341083.
    PubMed    


  126. ABOLFOTOUH S, Rautio T, Klintrup K, Helavirta I, et al
    Predictors of quality-of-life after ileal pouch-anal anastomosis in patients with ulcerative colitis.
    Scand J Gastroenterol. 2017 Jun 9:1-8. doi: 10.1080/00365521.2017.1337218.
    PubMed     Abstract available


  127. CON D, Jackson B, Gray K, De Cruz P, et al
    eHealth for inflammatory bowel disease self-management - the patient perspective.
    Scand J Gastroenterol. 2017 Jun 9:1-8. doi: 10.1080/00365521.2017.1333625.
    PubMed     Abstract available


  128. ROTHSCHILD B, Rinawi F, Herman Y, Nir O, et al
    Prognostic significance of granulomas in children with Crohn's disease.
    Scand J Gastroenterol. 2017;52.
    PubMed     Abstract available


  129. CARDILE S, Alterio T, Candusso M, Pietrobattista A, et al
    Autoimmune liver diseases and inflammatory bowel diseases in children: current issues and future perspectives.
    Scand J Gastroenterol. 2017;52.
    PubMed     Abstract available


    May 2017
  130. MACALUSO FS, Renna S, Maida M, Dimarco M, et al
    Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
    Scand J Gastroenterol. 2017 May 29:1-7. doi: 10.1080/00365521.2017.1333626.
    PubMed     Abstract available


  131. JACKSON B, Con D, Ma R, Gorelik A, et al
    Health care costs associated with Australian tertiary inflammatory bowel disease care.
    Scand J Gastroenterol. 2017 May 16:1-6. doi: 10.1080/00365521.2017.1323117.
    PubMed     Abstract available


  132. KOKKINIDIS DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, et al
    Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 May 14:1-9. doi: 10.1080/00365521.2017.1326163.
    PubMed     Abstract available


  133. SEO H, Chang K, Lee SH, Song EM, et al
    Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Scand J Gastroenterol. 2017 May 14:1-7. doi: 10.1080/00365521.2017.1323229.
    PubMed     Abstract available


  134. MARTELLI L, Colard A, Fontaine F, Deflandre J, et al
    Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea.
    Scand J Gastroenterol. 2017;52:564-569.
    PubMed     Abstract available


  135. SASIDHARAN S, Yajnik V, Khalili H, Garber J, et al
    Genetic risk factors for serious infections in inflammatory bowel diseases.
    Scand J Gastroenterol. 2017;52:570-576.
    PubMed     Abstract available


  136. VARMA P, Falconer J, Aga A, Prince HM, et al
    Rituximab-induced Crohn's disease.
    Scand J Gastroenterol. 2017;52:606-608.
    PubMed     Abstract available


  137. RINAWI F, Assa A, Eliakim R, Mozer-Glassberg Y, et al
    The natural history of pediatric-onset IBD-unclassified and prediction of Crohn's disease reclassification: a 27-year study.
    Scand J Gastroenterol. 2017;52:558-563.
    PubMed     Abstract available


  138. RYSKA O, Serclova Z, Mestak O, Matouskova E, et al
    Local application of adipose-derived mesenchymal stem cells supports the healing of fistula: prospective randomised study on rat model of fistulising Crohn's disease.
    Scand J Gastroenterol. 2017;52:543-550.
    PubMed     Abstract available


    April 2017
  139. KWAPISZ L, Gregor J, Chande N, Yan B, et al
    The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 20:1-5. doi: 10.1080/00365521.2017.1315740.
    PubMed     Abstract available


  140. LEE KE, Jung SA, Yoon H, Park SH, et al
    Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 7:1-7. doi: 10.1080/00365521.2017.1310288.
    PubMed     Abstract available


    March 2017
  141. JAIME F, Riutort MC, Alvarez-Lobos M, Hoyos-Bachiloglu R, et al
    Solar radiation is inversely associated with inflammatory bowel disease admissions.
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1307444.
    PubMed     Abstract available


  142. ERIKSSON C, Marsal J, Bergemalm D, Vigren L, et al
    Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1304987.
    PubMed     Abstract available


  143. WLODARCZYK M, Sobolewska-Wlodarczyk A, Cygankiewicz AI, Jacenik D, et al
    G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis.
    Scand J Gastroenterol. 2017 Mar 8:1-5. doi: 10.1080/00365521.2017.1298834.
    PubMed     Abstract available


  144. MURRAY IA, Murray LK, Woolson KL, Sherfi H, et al
    Incidence and predictive factors for positive 75SeHCAT test: improving the diagnosis of bile acid diarrhoea.
    Scand J Gastroenterol. 2017 Mar 5:1-6. doi: 10.1080/00365521.2017.1298153.
    PubMed     Abstract available


  145. MARTI-GALLOSTRA M, Myrelid P, Mortensen N, Keshav S, et al
    The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era.
    Scand J Gastroenterol. 2017;52:251-256.
    PubMed     Abstract available


  146. BAR-GIL SHITRIT A, Koslowsky B, Livovsky DM, Shitrit D, et al
    A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Scand J Gastroenterol. 2017;52:328-333.
    PubMed     Abstract available


    February 2017
  147. WALDUM HL, Bjornsson ES, Brenna E
    Chronic cholestatic liver diseases.
    Scand J Gastroenterol. 2017 Feb 28:1. doi: 10.1080/00365521.2017.1296276.
    PubMed    


  148. BOND A, Dodd S, Fisher G, Skouras T, et al
    Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy.
    Scand J Gastroenterol. 2017;52:204-208.
    PubMed     Abstract available


    January 2017
  149. YE X, Liu S, Hu M, Song Y, et al
    CCR5 expression in inflammatory bowel disease and its correlation with inflammatory cells and beta-arrestin2 expression.
    Scand J Gastroenterol. 2017 Jan 31:1-10. doi: 10.1080/00365521.2017.1281435.
    PubMed     Abstract available


  150. JACKSON BD, Con D, Liew D, De Cruz P, et al
    Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jan 27:1-7. doi: 10.1080/00365521.2017.1278785.
    PubMed     Abstract available


  151. LANDERHOLM K, Abdalla M, Myrelid P, Andersson RE, et al
    Survival of ileal pouch anal anastomosis constructed after colectomy or secondary to a previous ileorectal anastomosis in ulcerative colitis patients: a population-based cohort study.
    Scand J Gastroenterol. 2017 Jan 19:1-5. doi: 10.1080/00365521.2016.1278457.
    PubMed     Abstract available


  152. RONNBLOM A, Holmstrom T, Karlbom U, Tanghoj H, et al
    Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009.
    Scand J Gastroenterol. 2017;52:81-86.
    PubMed     Abstract available


  153. VALERIO DE AZEVEDO S, Maltez C, Lopes AI
    Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Scand J Gastroenterol. 2017;52:29-33.
    PubMed     Abstract available


  154. BEAUPEL N, Brouquet A, Abdalla S, Carbonnel F, et al
    Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn's disease.
    Scand J Gastroenterol. 2017;52:5-10.
    PubMed     Abstract available


    December 2016
  155. GRIMSTAD T, Skoie IM, Doerner J, Isaksen K, et al
    TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Scand J Gastroenterol. 2016 Dec 31:1-5. doi: 10.1080/00365521.2016.1273382.
    PubMed     Abstract available


  156. CANCADO GG, Vilela EG
    Guillain-Barre syndrome during adalimumab therapy for Crohn s disease: coincidence or consequence?
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  157. LAURELL A, Sjoberg K
    Prebiotics and synbiotics in ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  158. BROMS G, Granath F, Stephansson O, Kieler H, et al
    Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
    Scand J Gastroenterol. 2016;51:1462-1469.
    PubMed     Abstract available


    November 2016
  159. OLBJORN C, Cvancarova Smastuen M, Thiis-Evensen E, Nakstad B, et al
    Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  160. AMCOFF K, Stridsberg M, Lampinen M, Magnuson A, et al
    Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  161. LANKARANI KB, Sepehrimanesh M, Seghatoleslami F, Hoseini SE, et al
    Autophagy-related protein 7 level in patients with ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed    


  162. ZHOU G, Yang W, Yu L, Yu T, et al
    CD99 refers to the activity of inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  163. HUPPERTZ-HAUSS G, Hoivik ML, Jelsness-Jorgensen LP, Opheim R, et al
    Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  164. ENGLUND H, Liden K K, Lind T, Sundstrom T, et al
    Radiation exposure in patients with inflammatory bowel disease and irritable bowel syndrome in the years 2001-2011.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  165. MOLANDER P, Farkkila M, Kemppainen H, Blomster T, et al
    Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFalpha-blocking agents.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    October 2016
  166. JAKOBSSON GL, Sternegard E, Olen O, Myrelid P, et al
    Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    September 2016
  167. HOGBERG C, Karling P, Rutegard J, Lilja M, et al
    Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  168. MUTHAS D, Reznichenko A, Balendran CA, Bottcher G, et al
    Neutrophils in Ulcerative Colitis: A review of selected biomarkers and their potential therapeutic implications.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    August 2016
  169. LEHTOLA E, Haapamaki J, Farkkila MA
    Outcome of inflammatory bowel disease patients treated with TNF-alpha inhibitors: two-year follow-up.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  170. KISZKA-KANOWITZ M, Theede K, Mertz-Nielsen A
    Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  171. PROSBERG M, Bendtsen F, Vind I, Petersen AM, et al
    The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    July 2016
  172. HOLT DQ, Strauss BJ, Lau KK, Moore GT, et al
    Body composition analysis using abdominal scans from routine clinical care in patients with Crohn's Disease.
    Scand J Gastroenterol. 2016;51:842-7.
    PubMed     Abstract available


    June 2016
  173. VON VOLKMANN HL, Nylund K, Tronstad RR, Hovdenak N, et al
    An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    January 2016
  174. MOUSSATA D, Boschetti G, Stefanescu C, Nancey S, et al
    Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn's disease.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  175. FERREIRO-IGLESIAS R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Munoz JE, et al
    Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Scand J Gastroenterol. 2016;51:442-7.
    PubMed     Abstract available


  176. PARK SK, Hong M, Ye BD, Kim KJ, et al
    Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:684-91.
    PubMed     Abstract available


  177. DIGE A, Magnusson MK, Ohman L, Hvas CL, et al
    Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-alpha treatment in patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:692-9.
    PubMed     Abstract available


  178. GABRYEL M, Skrzypczak-Zielinska M, Kucharski MA, Slomski R, et al
    The impact of genetic factors on response to glucocorticoids therapy in IBD.
    Scand J Gastroenterol. 2016;51:654-65.
    PubMed     Abstract available


  179. HERRANZ BACHILLER MT, Barrio Andres J, Fernandez Salazar L, Ruiz-Zorrilla R, et al
    The utility of faecal calprotectin to predict post-operative recurrence in Crohns disease.
    Scand J Gastroenterol. 2016;51:720-6.
    PubMed     Abstract available


  180. COELHO R, Magro F, Silva M, Macedo G, et al
    Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis?
    Scand J Gastroenterol. 2016;51:679-83.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: